Home > LSE Health and Social Care > Who's who > LSE Health > profiles > Professor Elias Mossialos

Professor Elias Mossialos


Elias Mossialos is Brian Abel-Smith Professor of Health Policy within the Department of Social Policy at the London School of Economics and Political Science (LSE), and Director of LSE Health. He is also Professor of Health Policy and Management and Co-Director of the Centre for Health Policy at Imperial College London. His research interests concentrate on health systems and policy, addressing questions related to funding health care, private health insurance, pharmaceutical policies, the impact of EU law on health care systems, cancer care and policy and antibiotics. His work has been translated into Japanese, Russian, Greek and Spanish. He has more than 200 publications, including books, book chapters and articles in peer-review journals in the fields of public policy, health policy and economics and political science.

He is a Fellow of the Faculty of Public Health (FFPH) and Fellow of the Royal Colleges of Physicians of London and Edinburgh, and Honorary NHS Consultant in Public Health (South East London NHS Strategic Health Authority). He is a Visiting Professor at the Harris School of Public Policy, University of Chicago, Affiliate Professor at Imperial College Business School and Honorary Professor at the University of Copenhagen, the London School of Hygiene & Tropical Medicine (LSHTM), and L'Ecole des Hautes Etudes en Santé Publique in France. Professor Mossialos is a member of ASPHER's Honours Committee, the World Health Organization’s (WHO) European Advisory Committee on Health Research and the Health, Demographic Change and Well-being Advisory Group for the Horizon 2020 Research Programme of the European Commission.

In 2010 he was awarded the Andrija Stampar medal by the Association of Schools of Public Health in Europe (ASPHER) and the European Public Health Association (EUPHA), for contributions to European public health. He received the 2002 and 2007 Baxter Awards from the European Health Management Association for the best publication in health policy and management in Europe and a Commended Prize in the 2002 BMA Medical Book Competition. In 2009, under his directorship, LSE Health and Social Care was honoured with the biennial Queen's Anniversary Prize for Higher and Further Education. The Prize recognises outstanding achievement and excellence in UK universities and colleges and sits within the national honours system.

He has advised the WHO, European Parliament, European Commission (EC), World Bank, UK Office of Fair Trading, Ministries of Health and Social Affairs in Belgium, Brazil, China, Cyprus, Finland, Greece, Ireland, Kazakhstan, Russia, Slovenia, South Africa, Spain and Sweden, and health insurance funds in Austria, Croatia, France, Hungary and South Korea. He was a member of the management board of the European Medicines Agency (2000-2003) and the board of the Hellenic National Medicines Agency (2000-2002) and contributed to the International Forum on 'Common access to health care services' co-ordinated by the health ministers of Sweden, the UK and New Zealand.

In 1996 Professor Mossialos founded LSE Health, currently LSE's largest research centre with 60 staff working on a wide range of research, combining technical competence with policy mindedness. The Centre also fosters the training of young researchers and funds several doctoral and post-doctoral students; since 2004, the Centre has contributed more than £1.5 million of its own funds to support its PhD students. In 2009 the LSE's Research Committee highlighted the Centre's PhD programme and postdoctoral support systems as “exemplary”.

In 1998, Professor Mossialos co-founded the European Observatory on Health Systems and Policies, a major health policy research and knowledge transfer programme. The Observatory is a partnership between the World Health Organization (Regional Office for Europe), the European Commission, the World Bank, the Governments of Belgium, Finland, Ireland, Norway, Slovenia, Sweden, Switzerland, the United Kingdom, the French National Health Insurance Fund (Caisse nationale de l'assurance maladie des travailleurs salariés), the Veneto Region of Italy, LSE and LSHTM.  He is currently Co-Director of the Observatory. The Observatory supports and promotes evidence-based health policy-making through comprehensive and rigorous analysis of the dynamics of health care systems in Europe. The Observatory produces internationally recognised country health system reports and policy briefs, and organises 'policy dialogues' with ministries of health in Europe.

Professor Mossialos is associate editor (health policy) of the Journal Health Systems and Reform and of the European Heart Journal - Quality of Care & Clinical Outcomes. In 1995 he founded Eurohealth, a quarterly health policy journal bridging academic scholarship and policy-making, and since 1998 has been editor in chief of the Health Systems in Transition reviews published by the WHO.

Professor Mossialos established the MSc in International Health Policy at LSE in 1999, which has attracted high quality students from more than 90 countries, and in 2009 a modular MSc in Health Economics, Policy and Management, Europe's only modular MSc in the field, directed at mid-career professionals who lack the flexibility to participate in a traditional MSc programme. In 2014, in cooperation with the European Society of Cardiology, he established a modular MSc in Health Economics, Outcomes and Management. In 2014 he also established an interdisciplinary MSc in Global Health. He is planning to launch a dual executive Master programme in Global Health Policy in cooperation with the University of Chicago in 2018.

Selected publications

  1. Salas-Vega S, Iliopoulos O., Mossialos E. Overall survival, quality of life, and safety benefits from new cancer medicines: therapeutic improvements from a decade of innovation. JAMA Oncology 2016 (in press)
  2. Renwick M, Simpkin V, Mossialos E. Targeting Innovation in Antibiotic Drug Discovery. Copenhagen: World Health Organization and Ministry of Health, Welfare and Sports, The Netherlands, 2016.
  3. Mossialos E, Ge Y, Hu J, Wang L. Pharmaceutical policy in China: Challenges and opportunities for reform. Copenhagen: World Health Organization, 2016.
  4. Yang W, Jingwei He A, Fang L, Mossialos E. Financing institutional long-term care for the elderly in China: a policy evaluation of new models. Health Policy and Planning. 2016 (in press)
  5. Salas-Vega S, Mossialos E. Cancer Drugs Provide Positive Value In Nine Countries, But The United States Lags In Health Gains Per Dollar Spent. Health Aff (Millwood). 2016;35(5):813-23.
  6. Hu J, Mossialos E. Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts. Health Policy. 2016;120(5):519-34.
  7. Brogan DM, Mossialos E. Systems, not pills: The options market for antibiotics seeks to rejuvenate the antibiotic pipeline. Social Science and Medicine 2016;151:167-72
  8. Naci H, Carter AW, Mossialos E. Why the drug development pipeline is not delivering better medicines. BMJ. 2015;351:h5542. doi: 10.1136/bmj.h5542.
  9. Renwick M, Brogan D, Mossialos E. A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics. Journal of Antibiotics 2016 Feb;69(2):73-88
  10. Wenzl M, McCuskee S, Mossialos E. Commissioning for equity in the NHS: rhetoric and practice Br Med Bull. 2015; 115(1):5-17
  11. Mossialos E, Naci H, Courtain E et al. From ”retailers” to health care providers: transforming the role of community pharmacists in chronic disease management. Health Policy 2015;119(5):628-39
  12. Mossialos E, Naci H, Courtain E. Expanding the role of community pharmacists: Policymaking in the absence of policy-relevant evidence? Health Policy 2013;111(2):135-48
  13. Kossarova L., Holland W., Mossialos E. 'Avoidable' mortality: a measure of health system performance in the Czech Republic and Slovakia between 1971 and 2008. Health Policy and Planning 2013;28(5):508-25
  14. Brogan D, Mossialos E. Incentives for new antibiotics: the Options Market for Antibiotics (OMA) Model. Globalization and Health 2013, 9:58  doi:10.1186/1744-8603-9-58
  15. Rudisill C., Costa-Font J., Mossialos E. Behavioral adjustment to avian flu in Europe during spring 2006: the roles of knowledge and proximity to risk, Social Science and Medicine 2012; 75 (8):1362-1371
  16. Mossialos E, Lear J. Balancing economic freedom against social policy principles: EC competition law and national health systems. Health Policy 2012;106(2): 127-138. 
  17. Morel CM, McGuire A, Mossialos E. The level of income appears to have no consistent bearing on pharmaceutical prices across countries. Health Aff (Millwood). 2011;30(8):1545-52. 
  18. Sorenson C, Naci H, Cylus J, Mossialos E. Evidence of comparative efficacy should have a formal role in European drug approvals. BMJ. 2011;343:d4849. doi: 10.1136/bmj.d4849. 
  19. Mossialos E., Permanand P., Baeten R., Hervey T.H. (eds). Health Systems Governance in Europe: The Role of EU Law and Policy. Cambridge: Cambridge University Press, 2010. 
  20. Smith P.C., Mossialos E., Papanicolas I., Leatherman S.(eds). Performance Measurement for Health System Improvement: Experiences, Challenges and Prospects. Cambridge: Cambridge University Press, 2010. 
  21. Thomson S., Foubister T., Mossialos E. Can user charges make health care more efficient? BMJ 2010; 341:c3759. 
  22. Mossialos E, Morel CM, Edwards S, Berenson J, Gemmill-Toyama M, Brogan D. Policies and Incentives for Promoting Innovation in Antibiotic Research. Copenhagen: World Health Organization, 2010
  23. Morel CM, Mossialos E. Stoking the antibiotic pipeline. BMJ. 2010 May 18;340:c2115. 
  24. Allin, S., Masseria, C., Mossialos, E. Measuring Socioeconomic Differences in Use of Health Care Services by Wealth Versus by Income. American Journal of Public Health, 2009;99(10):1849-1855.   
  25. Mossialos E., Srivastava D. Pharmaceutical policies in Finland: Challenges and opportunities. Ministry of Health and Social Affairs (Finland) and European Observatory on Health Systems and Policies. Copenhagen: World Health Organization, 2008. 
  26. Mladovsky P., Mossialos E. A Conceptual Framework for Community-Based Health Insurance in Low-Income Countries: Social Capital and Economic Development, World Development 2008;36(4):590-607. 
  27. Costa-Font J., Rudisill C., Mossialos E. Attitudes as an Expression of Knowledge and 'Political Anchoring': The Case of Nuclear Power and Radioactive Waste in the UK. Risk Analysis 2008;28(5):1273-1288. 
  28. Gemmil M., Thomson S., Mossialos E. What impact do prescription drug charges have on equity and efficiency? Evidence from high-income countries. International Journal for Equity and Health 2008;7:12. 
  29. Mossialos E., Costa-Font J., Rudisill, C. Does organ donation legislation affect individuals' willingness to donate their own or their relative's organs? Evidence from European Union survey data. BMC Health Services Research 2008;8:48doi. 
  30. Thomson S, Mossialos E. Regulating private health insurance in the European Union: the implications of single market legislation and competition policy. Journal of European Integration 2007;29(1): 89-107.
  31. Thomson S., E Mossialos E. Choice of public or private health insurance: learning from the experience of Germany and the Netherlands. Journal of European Social Policy 2006;16(4): 315-327.
  32. Brogan D., E Mossialos E. Applying the Concepts of Financial Options to Stimulate Vaccine Development. Nature Reviews: Drug Discovery 2006;5:641-647.  
  33. Mossialos E, Allin S, Davaki K. Analysing the Greek health system: a tale of fragmentation and inertia. Health Economics 2005;14(S1):S151-S168.
  34. King D, Mossialos E. The Determinants of Private Medical Insurance Prevalence in England. Health Services Research 2005; 40(1):195-212.
  35. Permanand G, Mossialos E. Constitutional asymmetry and pharmaceutical policy-making in the European Union. Journal of European Public Policy 2005;12(4):687-609.
  36. Mossialos E, Allin S M. Interest groups and health system reform in Greece. West European Politics 2005; 28(2):421-444.
  37. Davaki K, Mossialos E. Plus ça change: health sector reforms in Greece. Journal of Health Policy, Politics and Law 2005:30(1-2):143-168.
  38. Mossialos E, Allin S, Karras K, Davaki K. An investigation of Caesarean sections in three Greek hospitals. Eur J Public Health 2005 15:288-295.
  39. Mossialos E, Mrazek M, Walley T. (eds) Regulating pharmaceuticals in Europe: striving for efficiency, equity and quality. Buckingham: Open University Press, 2004.
  40. Mossialos E, Thomson S. Voluntary health insurance in the European Union. Copenhagen: World Health Organisation, 2004.
  41. Mossialos E, McKee M. The influence of EU Law on the social character of health care systems. Brussels: P.I.E. Peter Lang, 2002.
  42. Mossialos E, Thomson S. Voluntary Health Insurance in the EU: a critical assessment. International Journal of Health Services, 2002;32(1):19-88.
  43. Mossialos E, Dixon A, Figueras J, Kutzin J (eds) Funding health care: Options for Europe. Buckingham: Open University Press, 2002